Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study
- PMID: 34561608
- PMCID: PMC8882171
- DOI: 10.1038/s41386-021-01179-z
Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study
Abstract
There is concern that selective serotonin reuptake inhibitor (SSRI) treatment may increase the risk of suicide attempts or deaths, particularly among children and adolescents. However, debate remains regarding the nature of the relationship. Using nationwide Swedish registers, we identified all individuals aged 6-59 years with an incident SSRI dispensation (N = 538,577) from 2006 to 2013. To account for selection into treatment, we used a within-individual design to compare the risk of suicide attempts or deaths (suicidal behaviour) in time periods before and after SSRI-treatment initiation. Within-individual incidence rate ratios (IRRs) of suicidal behaviour were estimated. The 30 days before SSRI-treatment initiation was associated with the highest risk of suicidal behaviour compared with the 30 days 1 year before SSRI initiation (IRR = 7.35, 95% CI 6.60-8.18). Compared with the 30 days before SSRI initiation, treatment periods after initiation had a reduced risk-the IRR in the 30 days after initiation was 0.62 (95% CI 0.58-0.65). The risk then declined over treatment time. These patterns were similar across age strata, and when stratifying on history of suicide attempts. Initiation with escitalopram was associated with the greatest risk reduction, though CIs for the IRRs of the different SSRI types were overlapping. The results do not suggest that SSRI-treatment increases the risk for suicidal behaviour in either youths or adults; rather, it may reduce the risk. Further research with different study designs and in different populations is warranted.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures



Comment in
-
Learning about the course of suicidal behavior but not about the effects of SSRIs.Neuropsychopharmacology. 2022 Mar;47(4):803. doi: 10.1038/s41386-021-01224-x. Epub 2021 Nov 8. Neuropsychopharmacology. 2022. PMID: 34750569 Free PMC article. No abstract available.
-
Reply to Ploderl and Hengartner: learning about the course of suicidal behavior but not about the effects of SSRIs.Neuropsychopharmacology. 2022 Mar;47(4):804. doi: 10.1038/s41386-021-01254-5. Epub 2022 Jan 12. Neuropsychopharmacology. 2022. PMID: 35022538 Free PMC article. No abstract available.
Similar articles
-
Predicting risk of suicidal behaviour after initiation of selective serotonin reuptake inhibitors in children, adolescents and young adults: protocol for development and validation of clinical prediction models.BMJ Open. 2023 Aug 23;13(8):e072834. doi: 10.1136/bmjopen-2023-072834. BMJ Open. 2023. PMID: 37612105 Free PMC article.
-
Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk: a target trial emulation.Neuropsychopharmacology. 2023 Nov;48(12):1760-1768. doi: 10.1038/s41386-023-01676-3. Epub 2023 Jul 28. Neuropsychopharmacology. 2023. PMID: 37507510 Free PMC article.
-
Suicidality and self-injury with selective serotonin reuptake inhibitors in youth: Occurrence, predictors and timing.Acta Psychiatr Scand. 2022 Feb;145(2):209-222. doi: 10.1111/acps.13360. Epub 2021 Aug 26. Acta Psychiatr Scand. 2022. PMID: 34374070 Free PMC article.
-
How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality?Aust N Z J Psychiatry. 2006 Nov-Dec;40(11-12):941-50. doi: 10.1080/j.1440-1614.2006.01917.x. Aust N Z J Psychiatry. 2006. PMID: 17054562 Review.
-
[SSRIs (selective serotonin reuptake inhibitors) and suicidality in adults, adolescents and children].Tijdschr Psychiatr. 2009;51(6):387-93. Tijdschr Psychiatr. 2009. PMID: 19517368 Review. Dutch.
Cited by
-
Predicting risk of suicidal behaviour after initiation of selective serotonin reuptake inhibitors in children, adolescents and young adults: protocol for development and validation of clinical prediction models.BMJ Open. 2023 Aug 23;13(8):e072834. doi: 10.1136/bmjopen-2023-072834. BMJ Open. 2023. PMID: 37612105 Free PMC article.
-
Incidence and trend of cardiac events among children and young adults exposed to psychopharmacological treatment (2006-2018): A nationwide register-based study.Br J Clin Pharmacol. 2025 Mar;91(3):817-828. doi: 10.1111/bcp.16321. Epub 2024 Oct 24. Br J Clin Pharmacol. 2025. PMID: 39448545 Free PMC article.
-
The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses.Transl Psychiatry. 2025 Jun 16;15(1):202. doi: 10.1038/s41398-025-03410-7. Transl Psychiatry. 2025. PMID: 40523911 Free PMC article.
-
An exploratory study evaluating the 20 medications most commonly associated with suicidal ideation and self-injurious behavior in the FAERS database.BMC Pharmacol Toxicol. 2025 Jan 30;26(1):24. doi: 10.1186/s40360-025-00858-7. BMC Pharmacol Toxicol. 2025. PMID: 39885564 Free PMC article.
-
Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms.BMC Med. 2025 Jan 7;23(1):11. doi: 10.1186/s12916-024-03814-0. BMC Med. 2025. PMID: 39773705 Free PMC article. Review.
References
-
- WHO. Suicide prevention. 2021. https://www.who.int/health-topics/suicide#tab=tab_1. Accessed 23rd Sept 2021.
-
- Pratt LA, Brody DJ, Gu Q. Antidepressant use among persons aged 12 and over: United States, 2011–2014. NCHS Data Brief no. 283. Hyattsville, MD: National Center for Health Statistics. 2017. - PubMed
-
- Abbing-Karahagopian V, Huerta C, Souverein PC, de Abajo F, Leufkens HG, Slattery J, et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur J Clin Pharmacol. 2014;70:849–57. doi: 10.1007/s00228-014-1676-z. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical